characteristics are listed in the Table. A total of 53% presented with tissue loss. There were 119 of 400 (29%) who had SFA access, with technical success achieved in 115 (96.6%). There were no statistically significant differences in technical success (96.6% vs 93.1%; P ¼ .399), distal embolization (0% vs 0.3%; P ¼ .513), arterial perforation (0% vs 0.7%; P ¼ .525), dissection (0% vs 0.7%; P ¼ .620), and hematoma (0.8% vs 0.7%; P ¼ .3) between SFA and retrograde access, respectively. All patients were discharged to preprocedure dwelling. One SFA access patient presented with delayed bleeding requiring operative repair, prolonged hospitalization, and subsequent death. There were no access site occlusions in either group.
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A Objectives: While a common target of quality improvement initiatives, early readmission to hospital after major surgery fails to capture the quality of life and economic burden associated with outpatient health-related resource use. Within a large, single-payer regional health care system, we characterized 30-day costs and the risk of emergency department (ED) visit, readmission, or death following major vascular surgery.
Methods: We designed a population-based retrospective cohort study of patients who underwent elective major vascular surgery (carotid endarterectomy, endovascular aneurysm repair [EVAR] , open abdominal aortic aneurysm (AAA) repair, lower extremity bypass) in Ontario, Canada, between 2004 and 2015 . The outcomes of interest were ED visit, readmission, death, and costs to the Ministry of Health (acute inpatient, ED, rehabilitation, physician billing claims, home care) within 30 days of discharge. Multivariable regression models were used to characterize the association between predischarge variables and these outcomes.
Results: A total of 28,014 patients were identified, comprising 9639 carotid endarterectomies, 5403 EVARs, 7348 open AAA repairs, and 5779 lower extremity bypasses. Within 30-days of discharge, 2159 (7.7%) were readmitted to hospital and 11 patients died (0.04%). Nearly the same number, a total of 1894 (6.8%) patients, had visited an ED without requiring admission. Median time to ED visit or readmission was 7 days (interquartile range, 3-14 days). The distribution of costs within 30 days of discharge was positively skewed (median, $519; interquartile range, $174-$1438; maximum, $160,938). Less than 60% of the 30-day cost was attributable to readmission. Older age, female sex, greater comorbidity level, and a longer index admission length of stay were associated with increased 30-day cost.
Conclusions: A focus on hospital readmission significantly underestimates 30-day health-related resource use and costs after major vascular surgery.
Author Disclosures: M. Al-Omran: Nothing to disclose; C. de Mestral: Nothing to disclose; M. A. Hussain: Nothing to disclose; N. Manoharan: Nothing to disclose; G. Roche-Nagle: Nothing to disclose; K. Salata: Nothing to disclose. Objectives: Neurogenic thoracic outlet syndrome (nTOS) is the most common form of TOS and may occur from an injury, occupational stress, or athletic endeavors. While most patients with nTOS will improve after first rib resection and scalenectomy (FRRS), the prognostic risk factors for success remain unelucidated. Athletes are a very motivated and disciplined demographic and therefore should be a group more likely to respond to FRRS for nTOS than nonathletes. We hypothesized that athletes would do better after FRRS than nonathletes despite the added physical stress that sporting activity would impose.
Methods: We reviewed our office records for every patient treated for TOS from July 2009-May 2014 and extracted demographic, historical, procedural and follow-up data. Following Institutional Review Board approval, we contacted these patients to complete a survey (Table II) to assess patient-centered outcomes of FRRS. We then compared athlete vs nonathlete survey responses.
Results: A total of 564 patients had FRRS for nTOS and 184 responded to the survey (Table II) . Survey results revealed 87% were improved in pain medication use (athletes 93% vs nonathletes 80%; P ¼ .013), 77% would undergo FRRS on the contralateral side if needed (athletes 75% vs nonathletes 79%; P ¼ .49), 73% had resolution of TOS symptoms (athletes 80% vs nonathletes 65%; P ¼ .02), and 86% could perform activities of daily living without limitation (athletes 95% vs nonathletes 77%; P ¼ .0004). Although 24% of respondents required another non-TOS procedure (athletes 27% vs nonathletes 22%; P ¼ .6), overwhelmingly 89% felt that they had made the right decision (athletes 93% vs nonathletes 80%; P ¼ .09). Multivariate analysis of age, race, gender, previous surgery, preoperative physical therapy, preoperative narcotic use, and athletic status confirmed that athletic status was an independent predictor for improvement in pain medication use (P ¼ .004), complete TOS resolution (P ¼ .016), and ability to perform ADLs (P ¼ .001).
Conclusions: Most patients undergoing FRRS for nTOS are improved and satisfied with the result and indicate they made the correct choice to have FRRS. While being an athlete was an independent variable for better outcomes in activity and pain medication use, their satisfaction following FRRS was equivalent to nonathletes. Further investigation needs to be done to determine whether these findings are due to physical and/or psychosocial factors. Objectives: Drug abusers present with different physiologic milieu, comorbidities, and risk factors compared to other vascular surgery patients. This study evaluated the outcomes of peripheral revascularization in this patient population.
Methods: A retrospective study of the Premier Database 2009 to 2015 was performed. In-hospital complications, mortality, and hospitalization cost were assessed in patients known to be drug abusers (opioids, sedatives, hypnotics, anxiolytics, cocaine, hallucinogens, antidepressants, and amphetamines) who underwent lower extremity revascularization (LER). Univariate, multivariate logistic, and generalized linear models were used.
Results: Our cohort included 209,838 patients, of which 1543 (0.7%) were drug abusers (59.1% opioids). Compared to nonabusers, drug abusers were younger (56.7 6 9.4 vs 67.8 6 11.1 years; P < .001) and more likely to be men (66.8% vs 57.6%; P < .001) and single (58.8% vs 42.4%; P < .001). This group of patients had more African Americans (28.3% vs 11.5%; P < .001) and was more likely to have chronic obstructive pulmonary disease (38.4% vs 26.5%; P < .001), myocardial infarction history (33.4% vs 22.3%; P < .001), congestive heart failure (25.7% vs 17.2%; P < .001), renal disease (24.4% vs 20.9%; P ¼ .001), liver disease (9.3% vs 1.4%; P < .001), critical limb ischemia (36.3% vs 25.0%; P < .001), diabetes with complications (15.5% vs 10.0%; P < .001), and HIV (1.2 vs 0.1%; P < .001) compared to nondrug abusers. In the bypass cohort (n ¼ 49,945), 560 (1.1%) were drug abusers. Those patients had more in-hospital complications (Fig) and were more destined for nonhome discharge (57.3% vs 45%; P < .001). Median hospital length of stay (LOS) was 7 days (interquartile range [IQR] ¼ 4, 12) vs 5 days (IQR ¼ 3, 8) in nonabusers. On the other hand, 983 patients were drug abusers in the stenting cohort (0.6%). They were also at significantly higher risk for in-hospital complications and nonhome discharge (30% vs 15.2%; P < .001). Median LOS was 4 days (IQR ¼ 2, 8) compared to 1 day (IQR ¼ 0, 3) in nonabusers (P < .001). On multivariate analysis, drug use was shown to have no 
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